Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue declined from ¥38 million in the same period of the previous year to ¥8 million, while research and development expenses increased from ¥482 million to ¥798 million and finance costs increased from ¥2,108 million to ¥2,659 million.
Description of material events and conditions provided. The company has determined that, although conditions exist that raise significant doubt about its ability to continue as a going concern, due to the operating loss of ¥1,130 million and negative cash flow from operating activities of ¥1,270 million, there is no material uncertainty because response measures are being implemented. No applicable matter is stated in the notes.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥8 million (YoY -78.2%) |
| Operating profit | ¥-1,130 million |
| Ordinary income | ¥-3,464 million |
| Profit attributable to owners of the parent | ¥-3,478 million |
| Net income per share | -¥27.65 |
| Equity ratio | End of the current fiscal period 32.1 / End of previous period 28.7 |
| Total assets | ¥23,484 million |
| Net assets | ¥7,577 million |
| Cash flows from operating activities | ¥-1,270 million |
| Cash flows from investing activities | ¥-723 million |
| Cash flows from financing activities | ¥7,146 million |
| Cash and cash equivalents at end of period | ¥10,868 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not provided because it is currently not possible to calculate a reasonable earnings forecast |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥70 million |
| Disclosure regarding the going concern assumption | Description of material events and conditions provided. The company has determined that, although conditions exist that raise significant doubt about its ability to continue as a going concern, due to the operating loss of ¥1,130 million and negative cash flow from operating activities of ¥1,270 million, there is no material uncertainty because response measures are being implemented. No applicable matter is stated in the notes. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Name of newly added company Not disclosed / Excluded 0 companies / Excluded Company Name Not disclosed |
| Material subsequent events | On 30 April 2026, the reduction in the amounts of share capital and capital surplus and the appropriation of surplus became effective. Share capital and capital surplus were each reduced by ¥1,215 million, and other capital surplus of ¥2,430 million was transferred to retained earnings brought forward and allocated to eliminate the deficit. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 135,002,200 |
| Treasury Shares at Period-End | 300 |
| Factors Behind Changes in Business Performance | Revenue declined from ¥38 million in the same period of the previous year to ¥8 million, while research and development expenses increased from ¥482 million to ¥798 million and finance costs increased from ¥2,108 million to ¥2,659 million. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.While revenue declined, research and development expenses increased from ¥482 million in the same period of the previous year to ¥798 million, and finance costs increased from ¥2,108 million to ¥2,659 million. The company has decided not to disclose a full-year forecast because numerous uncertain factors that could affect performance remain, including the possibility of business alliances and the acquisition of new drug seeds, making it difficult to calculate reasonable figures.